Runben Biotechnology (603193) 国元证券·2025-04-27 00:23Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [5][12]. Core Insights - The company achieved steady revenue and profit growth in 2024, with a revenue of 1.318 billion yuan, a year-on-year increase of 27.61%, and a net profit of 300 million yuan, up 32.8% year-on-year. The first quarter of 2025 saw accelerated growth, with revenue reaching 240 million yuan, a 44% increase year-on-year, and a net profit of 44 million yuan, up 24.6% year-on-year [2][5]. Revenue and Profitability - In 2024, the company's gross margin was 58.17%, an increase of 1.82 percentage points year-on-year, while the net margin was 22.77%, up 0.89 percentage points year-on-year. The sales expense ratio increased to 28.80%, while the management expense ratio decreased to 2.45% [2][5]. Product Performance - The baby care series generated 690 million yuan in revenue, a 32.42% increase year-on-year, while the mosquito repellent series saw revenue of 439 million yuan, up 35.39% year-on-year. The essential oil series achieved 158 million yuan in revenue, a 7.88% increase year-on-year [3]. Channel Strategy - Online sales accounted for a significant portion of revenue, with direct sales, platform distribution, and platform agency sales generating 774 million yuan, 165 million yuan, and 31 million yuan respectively, all showing year-on-year growth. The company is actively building a comprehensive sales network, maintaining a leading market share on platforms like Tmall, JD, and Douyin [4]. Future Earnings Forecast - The company is expected to achieve net profits of 394 million yuan, 507 million yuan, and 635 million yuan for the years 2025, 2026, and 2027 respectively, with corresponding earnings per share (EPS) of 0.97 yuan, 1.25 yuan, and 1.57 yuan [5][7].